# US 2026/0060977 A1 · Compositions and methods for treating protoporphyria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060977 A1
- Document ID: US20260060977A1
- Status: Published application
- Kind: A1
- Application number: 19/311,696
- Filed: 2025-08-27
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Applicants: Rutgers, the State University of New Jersey
- Inventors: Bishr Omary; Ning Kuo; Raheleh Nasrollahi
- Web page: https://patentgrep.com/patent/US20260060977A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4164: 1,3-Diazoles
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain embodiments of the invention provide a method of lowering Protoporphyrin IX (PP-IX) level or treating protoporphyria (e.g., EPP) in a subject in need of, comprising administering one or more antihistamines (e.g., administering an H1 antihistamine, or administering two antihistamines such as an H1 antihistamine and an H2 antihistamine) to the subject.

## Claims

### Claim 1

A method of treating protoporphyria related hepatobiliary disease in a subject in need of, comprising administering an H1 antihistamine to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the H1 antihistamine is administered for at least 5 days.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering a H2 antihistamine.

### Claim 4 (depends on 1)

The method of claim 1, wherein protoporphyrin-IX (PP-IX) level in liver is reduced.

### Claim 5 (depends on 2)

The method of claim 2, wherein PP-IX level in stool is increased.

### Claim 6 (depends on 1)

The method of claim 1, wherein the H1 antihistamine is chlorcyclizine (CCZ), fexofenadine (FXF), or cetirizine (CET).

### Claim 7 (depends on 1)

The method of claim 1, further comprising identifying the subject as having protoporphyria related hepatobiliary disease prior to administering the H1 antihistamine to the subject.

### Claim 8

A method of treating protoporphyria in a subject in need of, comprising administering two or more antihistamines to the subject.

### Claim 9 (depends on 8)

The method of claim 8, wherein the two or more antihistamines comprise a H1 antihistamine.

### Claim 10 (depends on 8)

The method of claim 8, wherein the two or more antihistamines comprise an H1 antihistamine and an H2 antihistamine.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antihistamines are administered for at least 5 days.

### Claim 12 (depends on 10)

The method of claim 10, wherein the subject has protoporphyria related hepatobiliary disease.

### Claim 13 (depends on 10)

The method of claim 10, wherein the subject has protoporphyria related skin disease.

### Claim 14 (depends on 10)

The method of claim 10, wherein the H1 antihistamine is chlorcyclizine (CCZ), fexofenadine (FXF), or cetirizine (CET).

### Claim 15 (depends on 10)

The method of claim 10, wherein the H2 antihistamine is cimetidine (CMT) or ranitidine (RNT).

### Claim 16

A method of treating protoporphyria in a subject in need of, comprising administering an H1 antihistamine to the subject, wherein the H1 antihistamine is administered for at least 5 days.

### Claim 17 (depends on 16)

The method of claim 16, wherein the subject has protoporphyria related skin or liver disease.

### Claim 18 (depends on 16)

The method of claim 16, wherein PP-IX level in circulating erythrocytes, serum or plasma is reduced.

### Claim 19 (depends on 16)

The method of claim 16, further comprising administering an H2 antihistamine to the subject.

### Claim 20 (depends on 16)

The method of claim 16, wherein the H1 antihistamine is chlorcyclizine (CCZ), fexofenadine (FXF), or cetirizine (CET).
